ReviewPharmacogenomics and personalized medicine2020
Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.
Review in Pharmacogenomics and personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The Role of Genetics in Stroke Risk and Outcome: A Review of Current Evidence.Brain and behavior · 2025Pooled it
- The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.Cardiovascular drugs and therapy · 2025Trial
- Effectiveness of CYP2C19 Genotype-Guided Antiplatelet Therapy Following Neurovascular Endovascular Procedures: A Prospective Non-Randomized Controlled Study.Therapeutics and clinical risk management · 2026Article
- Toward an integrated risk paradigm: personalizing antithrombotic therapy for coronary heart disease with gastrointestinal bleeding.Frontiers in cardiovascular medicine · 2026Article
- A case report: reflections on the formation of acute thrombotic events after PCI in patients with acute ST-Segment elevation myocardial infarction.International journal of emergency medicine · 2025Article
- Custom Gene Panel Analysis Identifies Novel Polymorphisms Associated with Clopidogrel Response in Patients Undergoing Percutaneous Coronary Intervention with Stent.International journal of molecular sciences · 2025Article
- Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.Scientific reports · 2025Article
- CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.Clinical and translational science · 2025Review
- Prevalence ofPharmacogenomics and personalized medicine · 2025Article
- Association ofBalkan journal of medical genetics : BJMG · 2024Article
- Article
- IsGenes · 2024Article
- Real-world evaluation ofPharmacogenomics · 2024Observational
- Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.Current neurology and neuroscience reports · 2023Review
- Pharmacogenetics of Antiplatelet Therapy.Annual review of pharmacology and toxicology · 2023Review
- Article
- Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.Pharmacogenomics · 2022Article
- P2Y12 inhibitors for the neurointerventionalist.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2022Review
- Evaluation of race and ethnicity disparities in outcome studies ofFrontiers in cardiovascular medicine · 2022Review
- Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.